<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0872-671X</journal-id>
<journal-title><![CDATA[Medicina Interna]]></journal-title>
<abbrev-journal-title><![CDATA[Medicina Interna]]></abbrev-journal-title>
<issn>0872-671X</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0872-671X2025000400005</article-id>
<article-id pub-id-type="doi">10.24950/rspmi.2762</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Triglyceride-Glucose Index as a Predictor of Cardiovascular Outcomes in Acute Coronary Syndrome Patients]]></article-title>
<article-title xml:lang="pt"><![CDATA[Índice Triglicerídeos-Glicose como Preditor de Outcomes Cardiovasculares em Doentes com Síndrome Coronária Aguda]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Rita Noversa de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[Andreia Sá]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[Mariana Campos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Sara de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Viana]]></surname>
<given-names><![CDATA[Susana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[João Caiano]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Local Health Unit of Matosinhos Pedro Hispano Hospital Serviço de Medicina Interna]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>32</volume>
<numero>4</numero>
<fpage>5</fpage>
<lpage>14</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0872-671X2025000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0872-671X2025000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0872-671X2025000400005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Cardiovascular diseases (CVD), particularly acute coronary syndromes (ACS), remain a leading cause of morbidity and mortality worldwide. Insulin resistance (IR) has emerged as a pivotal but underrecognized contributor to cardiovascular risk. The triglyceride-glucose (TyG) index is a simple and validated surrogate marker of IR and has shown promise in predicting adverse cardiovascular outcomes. However, its prognostic role in ACS remains underexplored. This study aimed to assess the impact of the TyG index on cardiovascular outcomes in patients admitted with ACS who underwent percutaneous coronary intervention (PCI). We further evaluated whether combining the TyG index with the GRACE score improves risk stratification and prognostic accuracy.  Methods:  We conducted a retrospective, single-centre, observational study including 534 adult patients admitted with ACS between January 2019 and December 2023. Patients were stratified into low and high TyG index groups (cut-off: 8.80) and low and high GRACE score groups (cut-off: 109). Demographic, clinical, laboratory, and angiographic data were collected. The primary endpoint was the incidence of major adverse cardio-vascular and cerebrovascular events (MACCE) at 12 months, including myocardial infarction (AMI), stroke, revascularization, and death. Kaplan-Meier survival analyses were performed.  Results:  High TyG index patients were significantly younger and had higher rates of diabetes, dyslipidaemia, obesity, and chronic kidney disease. Despite no significant differences in coronary anatomy or initial ACS presentation, metabolic markers were markedly worse in the high TyG group. TyG index alone was not associated with MACCE incidence but predicted AMI-free survival significantly better than the GRACE score (p=0.046 vs p=0.068). Combining TyG index and GRACE score revealed a statistically significant stratification for both MACCE-free and AMI-free survival (p&lt;0.0001 and p=0.030, respectively).  Conclusion:  The TyG index is an accessible and cost-effective tool that reflects IR and cardiometabolic burden. While not predictive of short-term MACCE alone, it enhances AMI risk stratification, particularly when combined with the GRACE score. These findings suggest that integrating metabolic markers like the TyG index into routine ACS risk models may improve long-term cardiovascular risk prediction.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  As doenças cardiovasculares (DCV), em particular a síndrome coronária aguda(SCA), continuam a ser uma das principais causas de morbilidade e mortalidade em todo o mundo. A resistência à insulina (RI) tem emergido como um fator determinante, embora frequentemente subvalorizado, no risco cardiovascular. O índice triglicerídeos-glicose (TyG) é um marcador simples e validado de RI, com potencial prognóstico para eventos cardiovasculares adversos. No entanto, o seu papel prognóstico na SCA permanece pouco estudado. O nosso objetivo foi avaliar o impacto do índice TyG nos outcomes cardiovasculares de doentes internados por SCA submetidos a intervenção coronária percutânea (ICP), e determinar se a sua combinação com o score GRACE melhora a estratificação de risco e a acuidade prognóstica.  Métodos:  Estudo observacional, retrospetivo e unicêntrico, incluindo 534 doentes adultos com diagnóstico de SCA entre janeiro de 2019 e dezembro de 2023. Os doentes foram estratificados em grupos de baixo e alto risco segundo o índice TyG (cut-off: 8,80) e o score GRACE (cut-off: 109). Foram recolhidos dados demográficos, clínicos, laboratoriais e angiográficos. O endpoint primário foi a ocorrência de eventos cardiovasculares e cerebrovasculares adversos maiores (MACCE) aos 12 meses, incluindo enfarte agudo do miocárdio (EAM), AVC, revascularização e morte. Foram realizadas análises de sobrevivência de Kaplan-Meier.  Resultados:  Os doentes com índice TyG elevado eram significativamente mais jovens e apresentavam maior prevalência de diabetes, dislipidemia, obesidade e doença renal crónica. Apesar de não se observarem diferenças significativas na anatomia coronária ou no tipo de apresentação do SCA, os marcadores metabólicos estavam marcadamente piores no grupo TyG elevado. Isoladamente, o índice TyG não se associou à incidência de MACCE, mas previu significativamente melhor a sobrevivência livre de EAM do que o score GRACE (p=0,046 vs p=0,068). A combinação de ambos permitiu uma estratificação estatisticamente significativa da sobrevivência livre de MACCE e EAM (p&lt;0,0001 e p=0,030, respetivamente).  Conclusão:  O índice TyG é um marcador acessível e de baixo custo que reflete a carga cardiometabólica e a resistência à insulina. Embora isoladamente não preveja MACCE a curto prazo, melhora a estratificação do risco de EAM, sobretudo quando combinado com o score GRACE. Estes dados sugerem que a integração de marcadores metabólicos como o TyG nos modelos de risco em SCA poderá melhorar a previsão de risco cardiovascular a longo prazo.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Acute Coronary Syndrome]]></kwd>
<kwd lng="en"><![CDATA[Biomarkers]]></kwd>
<kwd lng="en"><![CDATA[Triglycerides.]]></kwd>
<kwd lng="pt"><![CDATA[Biomarcadores]]></kwd>
<kwd lng="pt"><![CDATA[Síndrome Coronária Aguda]]></kwd>
<kwd lng="pt"><![CDATA[Triglicerídeos.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sacco]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Arnett]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Bonita]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gaziano]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The heart of 25 by 25 achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2016</year>
<volume>133</volume>
<page-range>e674-90</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piironen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ukkola]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Huikuri]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Havulinna]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Koukkunen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mustonen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in long-term prognosis after acute coronary syndrome]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2017</year>
<volume>24</volume>
<page-range>274-80</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Byrne]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Rossello]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Coughlan]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barbato]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chieffo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2023 ESC Guidelines for the management of acute coronary syndromes]]></article-title>
<source><![CDATA[Eur Heart J Acute Cardiovasc Care]]></source>
<year>2024</year>
<volume>13</volume>
<page-range>55-161</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancusi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de Simone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Best]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Roman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the strong heart study cohort]]></article-title>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2019</year>
<volume>18</volume>
<page-range>56</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Sobia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Niazi]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Manzoor]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Fazal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic clustering of risk factors evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistance]]></article-title>
<source><![CDATA[Diabetol Metab Syndr]]></source>
<year>2018</year>
<volume>10</volume>
<page-range>74</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minh]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Tien]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Sinh]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Thang]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Tay]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension]]></article-title>
<source><![CDATA[J Clin Hypertens]]></source>
<year>2021</year>
<volume>23</volume>
<page-range>529-37</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simental-Mendía]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Morán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero-Romero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects]]></article-title>
<source><![CDATA[Metab Syndr Relat Disord]]></source>
<year>2008</year>
<volume>6</volume>
<page-range>299-304</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Íñigo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro-González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Montero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pastrana-Delgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The TyG index may predict the development of cardiovascular events]]></article-title>
<source><![CDATA[Eur J Clin Invest]]></source>
<year>2016</year>
<volume>46</volume>
<page-range>189-97</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tao]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Hua]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglyceride-glucose index as a marker in cardiovascular diseases landscape and limitations]]></article-title>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2022</year>
<volume>21</volume>
<page-range>68</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Bai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglyceride-glucose index and coronary artery disease a systematic review and meta-analysis of risk, severity, and prognosis]]></article-title>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2023</year>
<volume>22</volume>
<page-range>170</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Vijayakumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolites as regulators of insulin sensitivity and metabolism.]]></article-title>
<source><![CDATA[Nat Rev Mol Cell Biol]]></source>
<year>2018</year>
<volume>19</volume>
<page-range>654-72</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riehle]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Abel]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin signaling and heart failure]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2016</year>
<volume>118</volume>
<page-range>1151-69</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Ferder]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Manucha]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging role of nitric oxide and heatshock proteins in insulin resistance]]></article-title>
<source><![CDATA[Curr Hypertens Rep]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishikawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kukidome]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sonoda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fujisawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuhisa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Motoshima]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of mitochondrial ROS production in the pathogenesis of insulin resistance]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2007</year>
<volume>77</volume>
<page-range>S161-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[DeMarco]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Sowers]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy]]></article-title>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>144-53</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Parrish]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin resistance, cardiovascular stifening and cardiovascular disease]]></article-title>
<source><![CDATA[Metabolism]]></source>
<year>2021</year>
<volume>119</volume>
<page-range>154766</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Puymirat]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Carruthers]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Should patients with acute coronary disease be stratified for management according to their risk Derivation, external validation and outcomes using the updated GRACE risk score]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2014</year>
<volume>4</volume>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Miao]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Rui]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Addition of TyG index to the GRACE score improves prediction of adverse cardiovascular outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention A retrospective study]]></article-title>
<source><![CDATA[Front Cardiovasc Med]]></source>
<year>2022</year>
<volume>9</volume>
<page-range>957626</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Shan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Integrating Coronary Plaque Information from CCTA by ML Predicts MACE in Patients with Suspected CAD]]></article-title>
<source><![CDATA[J Pers Med]]></source>
<year>2022</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>596</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kolte]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yonetsu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Libby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fuster]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optical Coherence Tomography of Plaque Erosion JACC Focus Seminar Part 2/3]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2021</year>
<volume>78</volume>
<page-range>1266-74</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malaiapan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of intravascular ultrasound in percutaneous coronary intervention of complex coronary lesions]]></article-title>
<source><![CDATA[Cardiovasc Diagn Ther]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>1371-88</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cowie]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors mechanisms of cardiovascular benefit beyond glycaemic control]]></article-title>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2020</year>
<volume>17</volume>
<page-range>761-72</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ussher]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Drucker]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucagon-like peptide 1 receptor agonists cardiovascular benefits and mechanisms of action]]></article-title>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2023</year>
<volume>20</volume>
<page-range>463-74</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dimitriadis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Adamopoulou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pyrpyris]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sakalidis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leontsinis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Manta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of SGLT2 inhibitors on the endothelium and the micro-circulation from bench to bedside and beyond]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Pharmacother]]></source>
<year>2023</year>
<volume>9</volume>
<page-range>741-57</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucagon-like peptide-1 receptor mechanisms and advances in therapy]]></article-title>
<source><![CDATA[Signal Transduct Target Ther]]></source>
<year>2024</year>
<volume>9</volume>
<page-range>234</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
